$AMRZ

Brouwer Roald purchased $70K of AMRZ

Brouwer Roald (Chief Technology Officer) purchased 1,500 shares of Amrize Ltd (AMRZ) at $46.36 on 2026-08-11.

Original reporting
SEC EDGAR · Brouwer Roald
Published Aug 13, 2026, 3:41 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 13, 2026, 4:00 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$AMRZ
Neutral
low confidence
Mentioned
$AMRZ
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AMRZNeutralLow
01

Why it matters

The newest disclosed fact is the CTO’s open-market purchase details (shares, price, total value, and post-transaction holdings).

02

Market read

Traders may note insider buying, but there is no accompanying fundamental catalyst in the text.

03

What to watch

No 10b5-1 plan is cited, but the filing still lacks context on motivation, timing constraints, or whether other insiders made concurrent trades.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-13, transaction dated 2026-08-11

Background

The article is an SEC Form 4 insider transaction disclosure for Amrize Ltd (AMRZ).

Company-level read

Ticker impact

$AMRZNeutralLow confidence
Context

Amrize Ltd CTO Brouwer Roald bought 1,500 shares on 2026-08-11 at $46.36, totaling $69,540, per Form 4.

Expected impact

Likely limited near-term impact; any effect is sentiment-only and typically fades unless followed by additional disclosures.

Evidence & confidence

Form 4 insider buys can signal confidence, but the filing provides no new operational or financial information and the transaction size is modest.

Market effects

No clear sector read-through from a single, modest insider purchase.

None indicated.

None indicated.

Counterpoint

The purchase may be discretionary or part of personal liquidity planning, not a forward-looking signal.

Key entities

  • Amrize Ltd

    Subject of the Form 4 insider transaction disclosure.

  • Brouwer Roald

    Chief Technology Officer who reported the open-market purchase.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

High

BofA downgrades Amrize to underperform, cuts price target on slower growth outlook

Bank of America downgraded Amrize to Underperform, cutting its price target to $40 from $50 due to slower earnings growth, market risks, and valuation concerns. The brokerage lowered its 2027-28 adjusted EBITDA and EPS estimates, citing stable U.S. cement prices, Canadian demand pressure from U.S. tariffs, and vulnerable roofing margins. BofA forecasts adjusted EBITDA growth of 3% and adjusted EPS growth of 6% annually over 2026-28, excluding large acquisitions. The bank also trimmed its buildin

$AMRZMed

BofA downgrades Amrize stock on growth concerns, cuts price target to $40

BofA Securities downgraded Amrize Ltd (NYSE:AMRZ) to Underperform, cutting its price target to $40 from $50. The stock is near its 52-week low, down 20% YTD. BofA reduced 2027-28 EBITDA estimates by 3%, citing growth concerns, U.S. cement price stability, and Canada macro risks. Amrize's Q2 earnings missed estimates, though revenue beat forecasts. Other analysts also downgraded the stock due to earnings misses and management changes.

High

Why is Amrize stock sliding today?

Amrize AG (AMRZ) fell 2.9% to CHF 34.13 after JPMorgan downgraded it to Neutral, citing executive departures and missed earnings. The stock hit a 52-week low of CHF 33.64, with JPMorgan lowering its price target to $52 from $57. The broader market showed no significant movement, indicating the decline is company-specific.